7Liu Fei,Yu Zhongzhen,Qiu Hong. Recombinant human throm-bopoietin recombinant human interleukin-11 for the treatment of lung cancer chemotherapy induced thrombocytopenia in [J].Chinese blood rheology of Journal,2010,10(1) : 117-119.
8Chen Jian,Qu Qin,Wei Yan,et al. Recombinant human throm-bopoietin recombinant human interleukin 11 tumor patients with thrombocytopenia[J]. Practical Journal of cancer, 2010,25 (3): 318-320.
9Lu Huimin,Lu Huiqing,Wang Jingchang.The recombinant human thrombopoietin and interleukin 11 in the treatment of leukemia after chemotherapy thrombocytopeni4J].To compare the efficacy of China. Journal of Clinical Pharmacology,2011,27(2) : 186-188.
9Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evalution of clinical studies. Blood, 2002, 100:3457- 3469.
10Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo- controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood, 2000, 95:2530-2535.
3Khellaf M, Viallard JF, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica, 2013, 98(6):881-887.
4Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am, 2013, 27(3):495-520.
5Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to beside. Br J Hematol, 2013, 161(6):778-793.
6Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 2013, 121(3):537- 545.
